CXCL12 and prostate cancer: SILAC-based quantitative proteomic analysis of lipid raft microdomains identified phosphatidylinositol 4-kinase III-alpha (PI4KA) as a novel downstream modulator of CXCL12/CXCR4 signaling in prostate cancer cells34.